Klivira
Request demo

Optimizing Enhertu Prior Authorization for Orthopedics

Navigating Enhertu prior authorization for orthopedics requires precise coordination across oncology treatment plans and specialized musculoskeletal interventions. Klivira streamlines this complex process, ensuring timely access to critical therapies and procedures.

For patients undergoing advanced cancer treatments like Enhertu, orthopedic complications such as bone metastases or pathological fractures necessitate specialized care. Revenue cycle directors and prior authorization coordinators face the challenge of aligning oncology-specific drug PAs with the distinct requirements for orthopedic imaging, procedures, and durable medical equipment. This intersection demands a robust PA strategy to prevent delays in patient care and optimize revenue capture.

The Intersection of Enhertu and Orthopedic Care Pathways

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate utilized in the treatment of HER2-positive cancers. While primarily an oncology medication, its use often coincides with orthopedic care for managing musculoskeletal complications such as bone metastases, pathological fractures, or spinal cord compression. Prior authorization for Enhertu itself follows oncology guidelines (e.g., NCCN, ASCO), but any associated orthopedic imaging, surgical interventions, or supportive devices require distinct orthopedic PA protocols.

Key Orthopedic Prior Authorization Categories in Oncology Support

  • Advanced imaging (MRI, CT) for metastasis detection or surgical planning.
  • Surgical interventions for pathological fractures or spinal instability.
  • Durable Medical Equipment (DME) for mobility support or post-operative care.
  • Orthobiologics and injections for pain management or bone health (where covered).
  • Physical and Occupational Therapy (PT/OT) for rehabilitation.

Documentation Requirements for Orthopedic Interventions Supporting Enhertu Patients

Prior authorization for orthopedic services in patients receiving Enhertu demands meticulous documentation. This includes comprehensive clinical notes detailing the orthopedic indication, correlation of symptoms with imaging, and often, a trial of conservative management where appropriate. For surgical procedures related to metastatic disease, documentation must clearly differentiate between prophylactic and palliative interventions, along with relevant oncology treatment history.

Common Orthopedic Denial Reasons in the Oncology Context

  • Insufficient documentation of clinical necessity for advanced imaging.
  • Lack of clear correlation between imaging findings and patient symptoms for surgical planning.
  • Incomplete conservative-care trial documentation for non-emergent orthopedic procedures.
  • Site-of-service discrepancies for surgical procedures (e.g., inpatient vs. outpatient).
  • Non-covered or investigational status of certain orthopedic adjunctive therapies.

Klivira's Role in Streamlining Complex PA Workflows

Klivira's platform integrates with EMRs to automate the collection of clinical data, supporting both oncology drug PAs and the associated orthopedic care. Our system orchestrates multi-step PA cascades, from diagnostic imaging to surgical intervention and post-operative DME, common in managing cancer-related musculoskeletal conditions. This reduces manual burden and accelerates approval times for patients on critical treatment paths like Enhertu.

Frequently asked questions

How does Klivira handle Enhertu PA when orthopedic procedures are also needed?

Klivira's platform is designed to manage complex, multi-step prior authorization processes. For Enhertu, the system supports the oncology-specific PA, while simultaneously orchestrating separate, but linked, PAs for any orthopedic imaging, surgical interventions, or DME required to manage cancer-related musculoskeletal complications. This ensures all components of care are addressed efficiently.

What specific orthopedic documentation does Klivira automate for patients on Enhertu?

For orthopedic PAs, Klivira automates the extraction of relevant clinical data from your EMR, including imaging reports, conservative-care trial documentation, physical exam findings, and surgical notes. This data is then structured to meet payer-specific requirements for procedures like spinal fusion or joint replacement, which may be indicated for metastatic disease.

Are specialty benefit managers involved in orthopedic PAs for Enhertu patients?

Yes, advanced musculoskeletal imaging is frequently routed through specialty benefit management vendors (e.g., those managing Carelon MBM or eviCore successor services). Klivira's platform is configured to identify and route these requests appropriately, integrating with vendor portals to streamline the submission process for orthopedic imaging PAs.

How does Klivira address conservative-care trial requirements for orthopedic procedures in oncology patients?

While some orthopedic interventions for advanced cancer may be emergent, elective procedures still require documentation of conservative-care trials. Klivira's system tracks trial duration, modalities, and patient response, aligning with guidelines such as those from AAOS, to support the clinical necessity argument for orthopedic PAs, even in the context of oncology.

What if an orthopedic procedure related to Enhertu treatment is denied?

In cases of denial, particularly for clinical necessity, Klivira facilitates the peer-to-peer review process. Our platform helps compile the necessary clinical evidence for the orthopedic surgeon-payer dialogue and tracks the appeal workflow, aiming to overturn denials and prevent delays in critical orthopedic care for patients undergoing Enhertu treatment.

Related coverage

Other enhertu prior authorization by payer

Other enhertu prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo